Učitavanje...
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
AIM: To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet‐Biedl syndrome (BBS). MATERIALS AND METHODS: Individuals aged 12 years and older with BBS received once‐daily setmelanotide. The dose was tit...
Spremljeno u:
| Izdano u: | Diabetes Obes Metab |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Blackwell Publishing Ltd
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7689750/ https://ncbi.nlm.nih.gov/pubmed/32627316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14133 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|